Neurophet receives FDA 510(k) Clearance for Neurophet AQUA

Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based

Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'

Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis

Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'

Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of